Related Experiment Video
Updated: Mar 28, 2026
06:40
Single-Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy Model in Mice
Published on: February 10, 2023
2.2K
Laparoscopic Sleeve Gastrectomy: Co-morbidity Profiles and Intermediate-Term Outcomes
Jonathan S Abelson1, Cheguevera Afaneh2, Patrick Dolan1
1Department of Surgery, Weill Cornell Medical Center, New York-Presbyterian Hospital, Weill Cornell Medical College, 525 East 68th St, Box 294, New York, NY, 10065, USA.
Obesity Surgery
|December 15, 2015
Summary
Laparoscopic sleeve gastrectomy (LSG) leads to significant weight loss and improved obesity-related conditions like diabetes and hypertension. This study shows sustained benefits over intermediate-term follow-up in a large patient cohort.
Area of Science:
- Bariatric surgery
- Metabolic and bariatric surgery
- Minimally invasive surgery
Background:
- Bariatric surgery, particularly laparoscopic sleeve gastrectomy (LSG), is recognized for its efficacy in promoting sustained weight loss and resolving obesity-related comorbidities.
- Existing research often lacks intermediate- to long-term follow-up data or involves smaller patient cohorts.
Purpose of the Study:
- To evaluate the intermediate-term effectiveness of LSG in a large cohort of morbidly obese patients.
- To assess weight loss and the resolution rates of common comorbidities including diabetes mellitus (DM), hypertension (HTN), and hyperlipidemia (HL) after LSG.
Main Methods:
- A retrospective review of 435 consecutive patients who underwent LSG between January 2004 and November 2013.
- Comorbidities (DM, HTN, HL) were assessed, with resolution defined as cessation of medication for that condition.
- Mean follow-up duration was 26 months (range: 1-112 months).
Main Results:
- Mean postoperative total weight loss (%TWL) remained significant up to 72 months, ranging from 23.6% to 29.9%.
- Significant reductions in the incidence of DM, HTN, and HL were observed at the last follow-up.
- Resolution rates for DM, HTN, and HL were 59%, 31%, and 50%, respectively. Medication use for these conditions also significantly decreased.
Conclusions:
- LSG demonstrates effectiveness in achieving substantial and lasting weight loss.
- The procedure significantly improves comorbidity profiles and reduces polypharmacy in morbidly obese patients over an intermediate follow-up period.
